Roche announced that it acquired Stratos Genomics, an early-stage sequencing technology company, to advance the development of Roche’s nanopore sequencer, according to a news release.
Roche said the investment will help it reach its goal of developing an end-to-end sequencing solution, starting from a patient sample to a diagnostic result.
Once developed, the Roche nanopore sequencer will utilize an approach that combines electronic and biological components to sequence DNA for fast, flexible, and cost-effective clinical diagnostic testing, the company said.
Stratos Genomics will continue operations in Seattle. Financial details of the agreement were not disclosed.
